Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

Area of Science:

• Nephrology
• Cardiology
• Clinical Trials

Background:

• Cardiovascular disease (CVD) is the primary cause of mortality in end-stage renal disease (ESRD) patients.
• Patients undergoing chronic hemodialysis represent a high-risk population for cardiovascular events.

Purpose of the Study:

• The AURORA trial is the first large-scale international study evaluating statin efficacy on cardiovascular outcomes in ESRD patients on chronic hemodialysis.
• This study aims to assess the impact of rosuvastatin on survival and cardiovascular events in this specific patient group.

Main Methods:

• 2,775 patients aged 50-80 years on chronic hemodialysis were randomized 1:1 to receive rosuvastatin 10 mg daily or placebo.
• The study involved 280 centers across 25 countries, with patients requiring at least 3 months of hemodialysis prior to screening.

Main Results:

• Baseline characteristics included a mean age of 64 years, 62% male, and 85% white patients.
• The median time on renal replacement therapy was 32 months.
• Mean total cholesterol was 4.53 mmol/l and mean LDL-C was 2.57 mmol/l at baseline.

Conclusions:

• The AURORA trial results are anticipated to influence current clinical guidelines regarding statin use in ESRD patients.
• Findings will provide critical insights into managing cardiovascular risk in patients with end-stage renal disease on hemodialysis.